USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
NOVAN, INC.
Address:
4222 Emperor Blvd, Suite 470
Durham, NC
Phone:
N/A
URL:
N/A
EIN:
120442768
DUNS:
621609556
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $2,635,120.00 7
SBIR Phase II $4,012,366.00 3

Award List:

STTR Phase 1: Nitric Oxide-Releasing Antibacterial Wound Dressing

Award Year / Program / Phase:
2008 / SBIR / Phase I
Award Amount:
$399,604.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Bacteria-related infection represents the most significant hurdle to normal wound healing resulting in gt100,000 deaths in the United States each year. Due to the emergence of antibiotic resistant bacteria and the conco mitant decrease in effective drug (i.e.,… More

Nitric Oxide-Releasing Wound Dressing for Preventing Chronic Wound Infections

Award Year / Program / Phase:
2010 / SBIR / Phase II
Award Amount:
$2,732,739.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Many wounds, such as surgical and traumatic injuries, heal without difficulty. Chronic wounds, however, typically exhibit delayed healing in patients with underlying medical conditions that prevent normal tissue repair. For example, approximately 15% of all… More

Nitric Oxide Releasing Catheter Coatings to Prevent Nosocomial Infections

Award Year / Program / Phase:
2010 / SBIR / Phase I
Award Amount:
$282,022.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): 1 Five million central venous catheters (CVCs) are inserted into patients in the US each year and up to 2 500,000 result in bloodstream infections with medical remediation costs ranging between 4,000 - 3 28,000 for ea ch incidence or 2 to 14 billion… More

SBIR Phase I:Scale-up Manufacturing of Nitric Oxide Nanotechnology for Healthcare Infections

Award Year / Program / Phase:
2010 / SBIR / Phase I
Award Amount:
$140,761.00
Agency:
NSF
Principal Investigator:
Abstract:
This Small Business Innovation Research (SBIR) Phase I project aims to develop a scale-up manufacturing process of nitric oxide-releasing silica nanoparticles. The main challenge is controlling the nanoparticle crystal size while maintaining high levels of nitric oxide storage. In this project,… More

Nitric Oxide-Releasing Intranasal Gel To Decolonize Biofilm-embedded S. Aureus

Award Year / Program / Phase:
2011 / SBIR / Phase I
Award Amount:
$598,952.00
Agency:
HHS
Principal Investigator:
Susanne Bauman – 919-485-8080
Abstract:
DESCRIPTION (provided by applicant): Staphylococcus aureus is the second leading cause of hospital-acquired bloodstream infections. In 2003, nearly 300,000 patients in US hospitals acquired an S. aureus infection, which accounted for nearly three million days of hospitalization, 9.5 billion in… More

Improving Host Response to Implantable Glucose Sensors via Nitric Oxide Release

Award Year / Program / Phase:
2011 / SBIR / Phase I
Award Amount:
$995,855.00
Agency:
HHS
Principal Investigator:
Nathan A. Stasko – 919-485-8080
Abstract:
DESCRIPTION (provided by applicant): Approximately 24 million adults and children in the United States have 1 Diabetes Mellitus (diabetes) and 1.6 million new cases are diagnosed each year. Type 2 is the most common form of the disease accounting for over90% of the diabetics worldwide. The remaining… More

Time-Released Nitric Oxide for the Treatment of Military Wound Infections

Award Year / Program / Phase:
2011 / SBIR / Phase I
Award Amount:
$69,821.00
Agency:
DOD
Principal Investigator:
Nathan Stasko, President – (919) 485-8080
Abstract:
Under battlefield conditions, warfighters face a wide range of cutaneous injuries, many of which are susceptible to life- and limb-threatening microbial infections caused by multi-drug resistant bacteria. Nitric oxide is a powerful, broad spectrum antimicrobial agent that is naturally produced by… More

SBIR Phase II: Scale-up Manufacturing of Nitric Oxide Nanotechnology for Healthcare Infections

Award Year / Program / Phase:
2012 / SBIR / Phase II
Award Amount:
$499,987.00
Agency:
NSF
Principal Investigator:
Abstract:
This Small Business Innovation Research (SBIR) Phase II project aims to develop the process and engineering controls necessary to scale up the manufacturing of a nitric-oxide-releasing active pharmaceutical ingredient (API). One of the applications is a wound-healing product for diabetic foot… More

Topical Nitric Oxide for the Treatment of Acute Military Wound Infections

Award Year / Program / Phase:
2012 / SBIR / Phase II
Award Amount:
$779,640.00
Agency:
DOD
Principal Investigator:
Nathan Stasko, President – (919) 485-8080
Abstract:
Under battlefield conditions, warfighters face a wide range of cutaneous injuries, many of which are susceptible to life- and limb-threatening infections caused by multi-drug resistant bacteria. Nitric oxide is a powerful, broad spectrum antimicrobial agent that is naturally produced by the immune… More

Use of a Nitric Oxide-Loaded Gel to Improve Healing Outcomes of Burn Injuries

Award Year / Program / Phase:
2012 / SBIR / Phase I
Award Amount:
$148,105.00
Agency:
HHS
Principal Investigator:
William R. Kelce – 919-354-2976
Abstract:
DESCRIPTION: Globally, an estimated 322,000 individuals die from fire-related burn injuries each year. In the United States, 450,000 experience burns requiring hospitalization and 3,500 of these lead to fatal outcomes. A burn of 30% of total body area cancost as much as 200,000 in initial… More